These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6349473)

  • 61. Epidemiological and experimental applications to occupational cancer prevention.
    Vainio H; Hemminki K
    J UOEH; 1989 Mar; 11 Suppl():323-45. PubMed ID: 2664947
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Comparison of the detecting mutagenic effect of two short microbiological tests].
    Li YH
    Zhonghua Zhong Liu Za Zhi; 1992 Nov; 13(6):419-22. PubMed ID: 1576907
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Application of the microbial mutation test in occupational health and its future problems (author's transl)].
    Takemura N
    Sangyo Igaku; 1981 Jul; 23(4):355-65. PubMed ID: 7321280
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 65. DNA-damaging activity in vivo and bacterial mutagenicity of sixteen hydrazine derivatives as related quantitatively to their carcinogenicity.
    Parodi S; De Flora S; Cavanna M; Pino A; Robbiano L; Bennicelli C; Brambilla G
    Cancer Res; 1981 Apr; 41(4):1469-82. PubMed ID: 7214329
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Studies on the efficiency of the Salmonella/rat hepatocyte assay for the detection of carcinogens as mutagens: activation of 1,2-dimethyl-hydrazine and procarbazine into bacterial mutagens.
    Malaveille C; Brun G; Bartsch H
    Carcinogenesis; 1983; 4(4):449-55. PubMed ID: 6340851
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A demonstration of the in vitro bacterial mutagenicity of procarbazine, using the microtitre fluctuation test and large concentrations of S9 fraction.
    Gatehouse DG; Paes DJ
    Carcinogenesis; 1983; 4(3):347-52. PubMed ID: 6339100
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Problems concerned with microbial mutagenicity tests].
    Gericke D
    Onkologie; 1982 Feb; 5(1):30-2, 34-5. PubMed ID: 6461834
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Artificial intelligence and Bayesian decision theory in the prediction of chemical carcinogens.
    Rosenkranz HS; Mitchell CS; Klopman G
    Mutat Res; 1985; 150(1-2):1-11. PubMed ID: 3889611
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The test that changed the world: The Ames test and the regulation of chemicals.
    Zeiger E
    Mutat Res Genet Toxicol Environ Mutagen; 2019 May; 841():43-48. PubMed ID: 31138410
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Series: 'Current issues in mutagenesis and carcinogenesis.' No. 42. Strategies and philosophies of genotoxicity testing: what is the question?
    Zeiger E
    Mutat Res; 1994 Jan; 304(2):309-14. PubMed ID: 7506375
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Assembly and preliminary analysis of a genotoxicity data base for predicting carcinogens.
    Palajda M; Rosenkranz HS
    Mutat Res; 1985 May; 153(3):79-134. PubMed ID: 3887150
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of multiple parameters of rodent carcinogenicity and in vitro genetic toxicity.
    Tennant RW; Stasiewicz S; Spalding JW
    Environ Mutagen; 1986; 8(2):205-27. PubMed ID: 3698943
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Rodent tumor profiles, Salmonella mutagenicity and risk assessment.
    Benigni R
    Mutat Res; 1990 May; 244(1):77-91. PubMed ID: 2336073
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Screening for possible human carcinogens and mutagens. False positives, false negatives: statistical implications.
    Lovell DP
    Mutat Res; 1989 Jul; 213(1):43-60. PubMed ID: 2747706
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Use of the bacterial reverse mutation assay to predict carcinogenicity of N-nitrosamines.
    Trejo-Martin A; Bercu JP; Thresher A; Tennant RE; Thomas RF; Cross K; Czich A; Waese K; Nicolette JJ; Murray J; Sonders P; Kondratiuk A; Cheung JR; Thomas D; Lynch A; Harvey J; Glowienke S; Custer L; Escobar PA
    Regul Toxicol Pharmacol; 2022 Nov; 135():105247. PubMed ID: 35998738
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Evolution of testing strategies for genetic toxicity.
    Brusick D
    Mutat Res; 1988; 205(1-4):69-78. PubMed ID: 3285199
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Mechanisms to stimulate research on assay systems to detect aneuploidy.
    de Serres FJ
    Basic Life Sci; 1985; 36():507-11. PubMed ID: 3913418
    [TBL] [Abstract][Full Text] [Related]  

  • 79. 3,7-dinitrofluoranthene.
    IARC Monogr Eval Carcinog Risks Hum; 1989; 46():189-94. PubMed ID: 2562782
    [No Abstract]   [Full Text] [Related]  

  • 80. Carcinogenicity testing of chemicals.
    Hess R
    J Toxicol Sci; 1987 May; 12(2):259-70. PubMed ID: 3305972
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.